Serum tetranectin is a significant prognostic marker in ovarian cancer patients

References

• Kjaerbye-Thygesen A, Frederiksen K, Høgdall EV, Glud E, Christensen L, Høgdall CK, Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:798–803.
   PubMed Web of Science ®Google Scholar
• NORDCAN, Version 3.4. Available online at: http://www-dep.iarc.fr/nordcan.htm. (accessed on May 14, 2009).
   Google Scholar
• Dansk Gynækologisk Cancer Database, Årsrapport 2006–2007. ISSN: 1902–7877.
   Google Scholar
• Qazi F, McGuire WP. The treatment of epithelial ovarian cancer. CA Cancer J Clin. 1995;45:88–101.
   PubMed Web of Science ®Google Scholar
• Bjorge T, Engeland A, Sundfor K, Trope CG. Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975–94 and treated at the Norwegian Radium Hospital. Acta Obstet Gynecol Scand. 1998;77:777–81.
   PubMed Web of Science ®Google Scholar
• Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266.
   PubMed Web of Science ®Google Scholar
• Høgdall CK, Christensen L, Clemmensen I. The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer. 1993;72:2415–22.
   PubMed Web of Science ®Google Scholar
• Høgdall CK, Høgdall EV, Hørding U, Clemmensen I, Nørgaard-Pedersen B, Toftager-Larsen K. Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand J Clin Lab Invest. 1993;53:741–6.
   PubMed Web of Science ®Google Scholar
• Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer. 2003;98:66–73.
   PubMed Web of Science ®Google Scholar
• Høgdall CK, Nørgaard-Pedersen B, Mogensen O. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Res. 2002;22:1765–8.
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Klug TL, St JE, Jenison E, Niloff JM, Lazarus H, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7.
   PubMed Web of Science ®Google Scholar
• Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2:275–85.
   PubMed Web of Science ®Google Scholar
• McGuckin MA, Layton GT, Bailey MJ, Hurst T, Khoo SK, Ward BG. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma – comparison with CA125. Gynecol Oncol. 1990;37:165–71.
   PubMed Web of Science ®Google Scholar
• Petri AL, Høgdall E, Christensen IJ, Kjaer SK, Blaakaer J, Høgdall CK. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. APMIS. 2006;114:359–63.
   PubMed Web of Science ®Google Scholar
• Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995;86:259–64.
   PubMed Web of Science ®Google Scholar
• Paramasivam S, Tripcony L, Crandon A, Quinn M, Hammond I, Marsden D, Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol. 2005;23:5938–42.
   PubMed Web of Science ®Google Scholar
• Makar AP, Kristensen GB, Kaern J, Børmer OP, Abeler VM, Tropé CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol. 1992;79:1002–10.
   PubMed Web of Science ®Google Scholar
• Makar AP. Prognostic studies in cancer of the ovary and fallopian tube with emphasis on the CA125 antigen on the CA125 antigen and c-erbB-2 oncogene. Acta Obstet Gynecol Scand. 1995;74:238–40.
   Web of Science ®Google Scholar
• Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002;100:59–64.
   PubMed Web of Science ®Google Scholar
• Høgdall CK, Hørding U, Nørgaard-Pedersen B, Toftager-Larsen K, Clemmensen I. Serum tetranectin and CA-125 used to monitor the course of treatment in ovarian cancer patients. Eur J Obstet Gynecol Reprod Biol. 1994;57:175–8.
   PubMed Web of Science ®Google Scholar
• Høgdall EVS, Høgdall CK, Christensen L, Glud E, Blaakaer J, Bock JE, Distribution of p53 Codon 72 Polymorp-hisms in Ovarian Tumour Patients and their Prognostic Significance in Ovarian Cancer Patients. Anticancer Res. 2002;22:1859–64.
   PubMed Web of Science ®Google Scholar
• Høgdall CK, Høgdall EV, Hørding U, Daugaard S, Clemmensen I, Nørgaard-Pedersen B, Plasma tetranectin and ovarian neoplasms. Gynecol Oncol. 1991;43:103–7.
   PubMed Web of Science ®Google Scholar
• Clemmensen I, Lund LR, Christensen L, Andreasen PA. A tetranectin-related protein is produced and deposited in extracellular matrix by human embryonal fibroblasts. Eur J Biochem. 1991;195:735–41.
   PubMedGoogle Scholar
• Westergaard UB, Andersen MH, Heegaard CW, Fedosov SN, Petersen TE. Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator. Eur J Biochem. 2003;270:1850–4.
   PubMedGoogle Scholar
• Diaz VM, Planaguma J, Thomson TM, Reventos J, Paciucci R. Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. Gastroenterology 2002;122:809–19.
   Web of Science ®Google Scholar
• Peterson HI, Kjartansson I, Korsan-Bengtsen K, Rudenstam CM, Zettergren L. Fibrinolysis in human malignant tumors. Acta Chir Scand. 1973;139:219–23.
   PubMedGoogle Scholar
• Hedner U, Nilsson IM. Clinical experience with determination of fibrinogen degradation products. Acta Med Scand. 1971;189:471–7.
   PubMedGoogle Scholar
• Deng X, Høgdall EV, Høgdall CK, Nørgaard-Pedersen B, Jørgensen M, Nielsen H, The Prognostic Value of Pretherapeutic Tetranectin and CA-125 in Patients with Relapse of Ovarian Cancer. Gynecol Oncol. 2000;79:416–19.
   PubMed Web of Science ®Google Scholar
• Begum FD, Høgdall CK, Kjaer SK, Christensen L, Blaakaer J, Bock JE, The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Anticancer Res. 2004;24:1981–5.
   PubMed Web of Science ®Google Scholar
• Høgdall CK, Høgdall EVS, Hørding U, Toftager-Larsen K, Arends J, Nørgaard-Pedersen B, The use of tetranectin, CA125 and CASA to predict residual tumor and survival at second and third look operations for ovarian cancer. Acta Oncol. 1996;35:63–9.
   PubMed Web of Science ®Google Scholar
• Aletti GD, Dowdy SC, Podrats KC, Cliby WA. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol. 2007;105:84–9.
   PubMed Web of Science ®Google Scholar
• Pomel C, Barton DP, McNeish I, Shepherd J. A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG. 2008;115:808–10.
   PubMed Web of Science ®Google Scholar
• Onda T, Matsumoto K, Shibata T, Sato A, Fukuda H, Konishi I;Japan Clinical Oncology Group. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol. 2008;38:74–7.
   PubMed Web of Science ®Google Scholar
• Vergote I, Trope CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IVovarian, fallopian tube and peritoneal cancer (OVCA). Abstract available online at: http://www.multiwebcast.com/igcs/2008/12th/2717/ignace.b.vergote.eortc-gcg.ncic-ctg.randomised.trial.comparing.primary.html. (accessed on May 14, 2009).
   Google Scholar
• Möbus V, Kreienberg R, Crombach G, Würz H, Caffier H, Kaesemann H, Evaluation of CA125 as a prognostic and predictive factor in ovarian cancer. J Tumor Marker Oncol. 1988;3:251–8.
   Google Scholar